Scionex

ScioNex is a clinical-stage biotechnology company based in South Korea that specializes in the development of small molecule immuno-oncology therapies. The company focuses on targeting the adenosine pathway, which plays a critical role in tumor-mediated immunosuppression. Its lead program, SNX-101, is a highly selective Adenosine A2A receptor antagonist designed to restore the activity of T cells and natural killer cells within the tumor microenvironment. ScioNex is currently advancing SNX-101 through Phase 1/2 clinical trials for the treatment of various advanced solid tumors. By leveraging its expertise in medicinal chemistry, the company aims to provide next-generation treatments for patients who are resistant to current checkpoint inhibitors.